Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

A partnership against epilepsy

A partnership against epilepsy
tavasat1

A partnership against epilepsy

A partnership against epilepsy
tavasat1

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis

  • In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024

Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
imberje1

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
arcticnovartis

MEDIA & INVESTOR RELEASE

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Ad hoc announcement pursuant to Art. 53

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
arcticnovartis

  • FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond
  • New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centers
Novartis at the J.P. Morgan Healthcare Conference 2024

Novartis at the J.P. Morgan Healthcare Conference 2024
angilma1